Markets
Luke Kawa
4/8/25

Stocks erase massive gains to end deep in the red on eve of reciprocal tariffs

The stock market’s recovery off the lows on Monday and early gains on Tuesday was a story of traders hoping and looking for off-ramps from reciprocal tariffs slated to go into effect at midnight. On Tuesday afternoon, the tale of the tape was traders driving in reverse on that off-ramp to create a major wreck on the highway.

The catalyst? Confirmation that the White House is going through with 104% tariffs on goods from China, not to mention the rest of the reciprocal tariffs.

The S&P 500 and Nasdaq 100 erased gains of 4% to finish 1.6% and 1.9% lower, respectively. The Russell 2000 gave up a 3% gain to finish 3% lower.

To say the market has been volatile would be an understatement: per Bespoke Investment Group, the past two days have been the first time in history that the Nasdaq 100 was down 4% only to finish positive, and then followed that up with a session where it was up 4% but ended in the red.

Every S&P 500 sector ETF fell, with materials, real estate, energy, consumer discretionary, and tech all off at least 2%.

The reversals were massive. Nvidia erased a gain of 8% to finish down 1.4%. Apple has nearly erased a year’s worth of gains, hitting a new low for 2025.

Levi’s surged after beating Q1 earnings, with the denim giant saying the impact of tariffs would be de nada. However, traders changed their minds, sending the stock from up 16% to down 8%.

Cannabis company Tilray cratered after missing on sales.

Some relative bright spots: health insurance stocks like Humana and UnitedHealth were the S&P 500’s top and third-top gainers, respectively, following reports that the Trump administration will boost payout rates for Medicare Advantage insurers. Broadcom rallied after management authorized a $10 billion buyback plan. Carnival gained after announcing an order for two new ships. And Boeing managed to stay in the green after reporting a significant improvement in first-quarter jet deliveries.

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.